Fig. 2From: How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directionsSchematic representation of SLN—loaded with antibody (own drawing). mAb monoclonal antibody, SLN solid lipid nanoparticles, IFX infliximab, ADM adalimumabBack to article page